Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 2
2017 4
2018 4
2019 2
2020 1
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Yao S, et al. Among authors: wathoo c. Sci Rep. 2022 May 24;12(1):8701. doi: 10.1038/s41598-022-12669-5. Sci Rep. 2022. PMID: 35610322 Free PMC article. Review.
Physician interpretation of genomic test results and treatment selection.
Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F. Brusco LL, et al. Among authors: wathoo c. Cancer. 2018 Mar 1;124(5):966-972. doi: 10.1002/cncr.31112. Epub 2017 Nov 22. Cancer. 2018. PMID: 29165790 Free PMC article.
Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA.
Sánchez NS, Kahle MP, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Javle M, Kaseb A, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Mills Shaw KR, Meric-Bernstam F. Sánchez NS, et al. Among authors: wathoo c. JCO Precis Oncol. 2019 Sep 24;3:PO.19.00017. doi: 10.1200/PO.19.00017. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32923868 Free PMC article.
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.
LeNoue-Newton ML, Chen SC, Stricker T, Hyman DM, Blauvelt N, Bedard PL, Meric-Bernstam F, Punglia RS, Schrag D, Lepisto EM, Andre F, Smyth L, Dogan S, Yu C, Wathoo C, Levy M, Eli LD, Xu F, Mann G, Lalani AS, Ye F, Micheel CM, Arnedos M. LeNoue-Newton ML, et al. Among authors: wathoo c. Clin Cancer Res. 2022 May 13;28(10):2118-2130. doi: 10.1158/1078-0432.CCR-21-0885. Clin Cancer Res. 2022. PMID: 35190802
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.
Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K. Meric-Bernstam F, et al. Among authors: wathoo c. JCO Precis Oncol. 2018;2018:PO.17.00245. doi: 10.1200/PO.17.00245. Epub 2018 Apr 25. JCO Precis Oncol. 2018. PMID: 30035249 Free PMC article.
Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.
Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hasset MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, Kundra R, Sweeney SM, Gao J, Schultz N, Zarski A, Gardos SM, Lee J, Sheffler-Collins S, Park BH, Sawyers CL, André F, Levy M, Meric-Bernstam F, Bedard PL, Iasonos A, Schrag D, Hyman DM; AACR Project GENIE Consortium. Smyth LM, et al. Among authors: wathoo c. Cancer Discov. 2020 Apr;10(4):526-535. doi: 10.1158/2159-8290.CD-19-1209. Epub 2020 Jan 10. Cancer Discov. 2020. PMID: 31924700 Free PMC article.
Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing.
Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, Yap TA, Arun B, Lu KH, Meric-Bernstam F. Nowlen CJ, et al. Among authors: wathoo c. J Immunother Precis Oncol. 2024 Feb 5;7(1):7-17. doi: 10.36401/JIPO-23-2. eCollection 2024 Feb. J Immunother Precis Oncol. 2024. PMID: 38327755 Free PMC article.
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.
Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Dumbrava EI, et al. Among authors: wathoo c. JCO Precis Oncol. 2019;3:PO.18.00143. doi: 10.1200/PO.18.00143. Epub 2019 Apr 11. JCO Precis Oncol. 2019. PMID: 31517177 Free PMC article.
Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes.
Daniels M, Wathoo C, Brusco L, Lu KH, Shaw K, Dumbrava EEI, Arun B, Strong L, Litton JK, Eterovic K, Aytac U, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Daniels M, et al. Among authors: wathoo c. JCO Precis Oncol. 2017;1:PO.17.00074. doi: 10.1200/po.17.00074. Epub 2017 Oct 31. JCO Precis Oncol. 2017. PMID: 31552380 Free PMC article. No abstract available.
15 results